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AbstrACt
Objectives The Prediciting factors for response to treatment 
in carpal tunnel syndrome (PALMS) study is designed to 
identify prognostic factors for outcome from corticosteroid 
injection and surgical decompression for carpal tunnel 
syndrome (CTS) and predictors of cost over 2 years. The aim 
of this paper is to explore the cross-sectional association of 
baseline  
patient-reported and clinical severity with anxiety, depression, 
health-related quality of life and costs of CTS in patients 
referred to secondary care.
Methods Prospective, multicentre cohort study initiated 
in 2013. We collected baseline data on patient-reported 
symptom severity (CTS-6), psychological status (Hospital 
Anxiety and Depression Scale), hand function (Michigan Hand 
Questionnaire) comorbidities, EQ-5D-3L (3-level version of 
EuroQol-5 dimension) and sociodemographic variables. Nerve 
conduction tests classified patients into five severity grades 
(mild to very severe). Data were analysed using a general 
linear model.
results 753 patients with CTS provided complete baseline 
data. Multivariable linear regression adjusting for age, sex, 
ethnicity, duration of CTS, smoking status, alcohol consumption, 
employment status, body mass index and comorbidities 
showed a highly statistically significant relationship between 
CTS-6 and anxiety, depression and the EQ-5D (p<0.0001 in 
each case). Likewise, a significant relationship was observed 
between electrodiagnostic severity and anxiety (p=0.027) but 
not with depression (p=0.986) or the EQ-5D (p=0.257). National 
Health Service (NHS) and societal costs in the 3 months prior 
to enrolment were significantly associated with self-reported 
severity (p<0.0001) but not with electrodiagnostic severity.
Conclusions Patient-reported symptom severity in CTS is 
significantly and positively associated with anxiety, depression, 
health-related quality of life, and NHS and societal costs 
even when adjusting for age, gender, body mass index, 
comorbidities, smoking, drinking and occupational status. In 
contrast, there is little or no evidence of any relationship with 
objectively derived CTS severity. Future research is needed 
to understand the impact of approaches and treatments that 
address psychosocial stressors as well as biomedical factors 
on relief of symptoms from carpal tunnel syndrome.
IntrOduCtIOn
Carpal tunnel syndrome (CTS) is the most 
common nerve entrapment syndrome; an 
estimated 1 in 10 people are likely to develop 
symptoms at some stage in their lives.1 CTS is 
characterised by pins and needles, pain and 
numbness, often affecting both hands. Symp-
toms can range from intermittent to constant 
and from very mild to very severe, potentially 
interfering significantly with daily activities.2 
Approximately one-third to two-thirds of 
patients with CTS go on to have surgery.3–5 
Such variations in surgical rates may be due 
to different follow-up periods in individual 
studies as well as differences in criteria for 
and access to surgical decompression.
Up to 54 000 carpal tunnel decom-
pressions were carried out in England in 
2014–2015 (Hospital Episode Statistics) at 
a cost of £46 million to the National Health 
Service (NHS) (based on an NHS tariff of 
£864) and are predicted to increase twofold 
by 2030.6 Clinical Commissioning Groups 
(CCG) in England have introduced guidelines 
on funding for procedures deemed to be of 
‘limited clinical value’, recommending carpal 
tunnel surgery only for those with ‘moderate to 
severe CTS’ or who have ‘not responded to conser-
vative measures’ (ie, corticosteroid injections 
strengths and limitations of this study
 ► Large multicentre prospective cohort study of carpal 
tunnel syndrome (CTS) (n>700).
 ► We used a multivariable model to test the 
independence of associations with a range of 
prespecified demographic and clinical variables.
 ► All patients had a diagnosis of CTS made through the 
combination of clinical history, signs and symptoms 
with objective electrodiagnostic testing.
 ► Cross-sectional analysis limited to baseline data 
only with longitudinal (2 years) follow-up still in 
progress.
 ► Cost data are limited to a 3-month horizon prior to 
enrolment.
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and splints). However, it is often unclear whether severity 
refers to pathophysiology or symptoms or a combination 
of both. A recent review of policies from 175 CCGs in 
England highlighted that these were highly variable in 
terms of criteria for defining severity, the necessity for 
nerve conduction studies (NCS) and duration of non-op-
erative treatment before referral for surgery is allowed.7 
Controversy continues over the best management of CTS 
at different stages. More recent research on CTS has high-
lighted the role of psychological factors such as anxiety, 
depression and patient’s health beliefs in how patients 
perceive their symptoms, their impact on function and 
the outcome from treatment.8–10 No previous studies have 
explored the association of disease and symptom severity 
with health-related quality of life (HRQoL) or costs from 
a personal and societal perspective and which may also 
play an important role in treatment planning.
The objectives of this cross-sectional analysis were (1) to 
explore the association of self-reported symptom severity 
and electrodiagnostic severity with anxiety, depression, 
hand function and HRQoL in patients referred for diag-
nosis and treatment of CTS; and (2) to describe NHS and 
societal costs of CTS in the 3 months preceding referral 
for nerve conduction testing and treatment and their 
association with carpal tunnel severity.
MethOds
design and study population
A prospective longitudinal cohort study (PALMS study) 
was initiated in 2013 to develop a multivariable prog-
nostic model of predictive factors for outcome after 
steroid injection, outcome after surgery and costs in CTS. 
The full study protocol has been described elsewhere.11 
Recruitment took place at five secondary care sites across 
five NHS trusts in England where patients had been 
referred by primary care for nerve conduction tests and 
prior to any treatment. Patients were diagnosed with CTS 
by a neurophysiologist or hand surgeon based on signs 
and symptoms, clinical history and objective measurable 
pathophysiology (NCS). Eligible patients were invited to 
participate by returning completed screening question-
naires and signed consent forms. Patients were included 
if they had CTS in at least one hand confirmed by NCS 
(grade ≥1) and were aged 18 years or over. NCS grading 
was done according to Bland’s criteria12 (for details, 
see online supplementary file 1). Patients with concom-
itant diseases such as diabetes or hypothyroidism were 
included. Exclusion criteria were previous surgery in the 
affected hand in the last 12 months, pregnancy or up 
to 12 months post partum, serious comorbidities, other 
limb mononeuropathies, sensory or motor disturbances 
secondary to stroke, multiple sclerosis or nerve injury and 
inability to speak or write English.
For the present study, data collected at baseline were 
used. Self-reported symptom severity and NCS for only 
one hand per patient were used. In patients with bilat-
eral CTS, the ‘index hand’ was defined as either the worst 
hand or the dominant hand where self-reported symptom 
severity on the CTS-6 was the same bilaterally.
data collection
A baseline questionnaire was developed comprising 
the following standardised and non-standardised 
questionnaires:
 ► Symptom severity was assessed with the six-item short-
ened form of the Boston Carpal Tunnel Question-
naire,13 the CTS-614 for each hand. The scores range 
from 1 (no symptoms) to 5 (very severe symptoms). 
A mean score of 1 indicates no symptoms (tingling, 
numbness and pain during the past 2 weeks).
 ► Hand functional status was assessed with three 
subscales of the Michigan Hand Questionnaire 
(MHQ)15 16: overall hand function for worst hand, 
unilateral and bilateral activities of daily living and 
work performance. Each subscale is converted into 
a percentage with higher values denoting greater 
disability.
 ► Psychological status was assessed using the Hospital 
Anxiety and Depression Scale (HADS).17 It is made 
up of 14 items, 7 relating to anxiety and 7 relating to 
depression. Responses are scored from 0 to 3 giving a 
possible score range of 0–21 for each subscale. Scores 
of 8–10 identify mild cases, 11–15 moderate cases and 
16 or more severe cases.17
 ► HRQoL was assessed by EQ-5D-3L (3-level version of 
EuroQol-5 dimension).18
 ► Comorbidities were collected by the Self-Adminis-
tered Comorbidity Questionnaire (SACQ).19 The total 
score ranges from 0 to 36 which is based on 12 listed 
conditions for which the patients indicate if they have 
it (1 point), receive treatment for it (2 points) and 
whether it is activity limiting (3 points).
 ► Healthcare resource use in the 3 months prior to 
enrolment. This included questions about treatments 
received (including alternative therapies), medica-
tions (prescription and over the counter), healthcare 
contacts (NHS primary, secondary and tertiary, and 
private), patient-reported days off work due to CTS 
and assistance with activities of daily living due to 
CTS.
Other clinical and demographic variables collected at 
baseline were age, sex, duration of symptoms, height and 
weight, work status and type, smoking status, alcohol units 
consumed per week, ethnicity and household income. 
Additionally, the full NCS reports of enrolled patients were 
obtained from the participating sites and were graded by 
the first author using Bland’s criteria12 from 1 (mild) to 6 
(extremely severe) (see online supplementary file 1).
Patients were given the option of completing the study 
questionnaires online via a personalised link to a pass-
word-protected web-based data entry system maintained 
by the Norwich Clinical Trials Unit or via paper-based 
questionnaires sent by mail.
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statistical analysis
A generalised linear model (GLM) with a normally distrib-
uted error term was used to model the HADS anxiety 
score, HADS depression score, MHQ scores and EQ-5D 
utility index. EQ-5D responses were converted to utili-
ties using UK-specific preference weights.20 The model 
included gender, age, ethnicity, employment status, 
smoking status, units of alcohol per week, body mass index 
(BMI), duration of CTS and comorbidity score as explan-
atory variables before adding either CTS-6 symptom score 
or NCS score. Parameter estimates for the effect of CTS-6 
and NCS score are provided with 95% CIs and statistical 
significance set at the conventional 5% level.
Resource use data were converted to cost per patient using 
standard UK unit cost sources (Personal Social Services 
Research Unit, British National Formulary and Office for 
National Statistics), the relevant published literature and 
consultation with experts. Costs were then modelled using 
a GLM with log-link and gamma distributed errors. The 
base year for the costs was 2015/2016 and the analysis was 
conducted from the perspectives of the NHS and society 
(defined as the sum of NHS and patient out-of-pocket costs 
and morbidity-related lost productivity).
results
Recruitment took place over 30 months between July 2013 
and December 2015. A total of 1918 patients with CTS 
were identified and invited to participate of which a total 
of 753 patients met all eligibility criteria and returned 
full baseline questionnaires (see STROBE (Strength-
ening the Reporting of Observational Studies in Epidemi-
ology) diagram in figure 1).
The sociodemographic and clinical variables of the 
cohort are summarised in tables 1 and 2. Bilateral CTS 
affected 69% of patients and 75% of participants had 
their symptoms for at least 6 months or longer. Using their 
Figure 1 STROBE (Strengthening the Reporting of 
Observational Studies in Epidemiology) flow chart.31 NCS, 
nerve conduction studies.
Table 1 Demographics
Number (%)
Sex
  Male 260 (35%)
  Female 493 (65%)
Age (years)
  Mean (SD) 60.3 (12.7)
Ethnicity
  White 731 (97%)
  Other 20 (3%)
  Missing 2
BMI
  Mean (SD) 28.7 (5.8)
Smoking status
  Current 76 (10%)
  Ex-smoker 299 (40%)
  Non-smoker 375 (50%)
  Missing 3
Alcohol intake (units)
  None 251 (34%)
  1–4 271 (37%)
  5–10 114 (15%)
  11–20 81 (11%)
  >21 25 (3%)
  Missing 11
Working status
  Working 296 (39%)
   Self-employed 88 (11.7%)
  Not working 457 (61%)
   Retired 322 (43%)
   Unemployed  14 (1.9%)
   Long-term sick 36 (4.8%)
   Carer, volunteer or student 85 (11.75%)
Income (per annum)
  <£15K 170 (23%)
  £15K–£21.5K 103 (14%)
  £21.5–£35K 148 (20%)
  £35K–£50K 81 (11%)
  >£50K 49 (7%)
  Missing 5
BMI, body mass index.
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worst hand as the index hand, only 18% had received a 
steroid injection and mean self-reported symptom severity 
(CTS-6) was 2.89 points. Based on nerve conduction tests, 
69% of patients had at least moderate CTS (grades ≥3), 
with 24% in the severe and very severe categories (grade 
5 or 6) (see table 2).
The mean CTS-6 scores increased steadily with NCS 
grade up to grade 6 (which contained relatively few indi-
viduals). The mean (and SD) by grade were as follows: 
grade 1, 2.69 (0.86); grade 2, 2.79 (0.85); grade 3, 2.87 
(0.91); grade 4, 3.00 (0.79); grade 5, 3.06 (0.79); grade 
6, 2.89 (0.78).
The HADS anxiety and HADS depression scores were 
within normal ranges (scores 0–7) in 66% and 80% of 
participants, respectively. Self-reported comorbidities are 
summarised in table 3. The mean SACQ score was 5.22. 
The three most common comorbidities were low back pain 
Table 2 Clinical characteristics
Number (%)
Duration of CTS
  <3 months 42 (6%)
  3–6 months 140 (19%)
  6–12 months 181 (24%)
  12–18 months 98 (13%)
  >18 months 292 (39%)
Side of CTS
  Left 89 (12%)
  Right 148 (20%)
  Bilateral 516 (69%)
Dominant hand affected 
  Yes 669 (89%)
  No 84 (11%)
Worst side
  Left 264 (35%)
  Right 489 (65%)
Worst Side NCS Grade
  1 150 (20%)
  2 79 (11%)
  3 202 (27%)
  4 137 (18%)
  5 159 (21%)
  6 24 (3%)
  Missing 2
CTS-6 (1–5)
  Mean (SD) 2.89 (0.85)
MHQ overall function (0–100)
  Mean (SD) 53.4 (22.6)
MHQ unilateral activities (0–100)
  Mean (SD) 66.6 (28.6)
MHQ bilateral activities (0–100)
  Mean (SD) 69.4 (25.5)
MHQ work (0–100)
  Mean (SD) 64.7 (25.6)
HADS Anxiety
  Mean (SD) 6.18 (4.52)
   Normal (1–7) 497 (66%) 
   Mild (8–11) 123 (16%) 
   Moderate (11–14)  90 (12%)
   Severe (15–21) 42 (6%) 
   Missing 1
HADS Depression
  Mean (SD) 4.48 (3.84)
   Normal (1–7) 602 (80%)
   Mild (8-10) 88 (12%)
Continued
Number (%)
   Moderate (11–14) 47 (6%)
   Severe (15–21) 15 (2%)
   Missing 1
Overall Co-morbidity Score (0–36)
  Mean (SD) 5.22 (4.17)
EQ-5D-3L VAS
  Mean (SD) 73.54 (18.2)
CTS, carpal tunnel syndrome; EQ-5D-3L, 3-level version of 
EuroQol-5 dimension; HADS, Hospital Anxiety and Depression 
Scale; MHQ, Michigan Hand Questionnaire; NCS, nerve 
conduction studies; VAS, visual analogue scale.
Table 2 Continued 
Table 3 Self-reported comorbidities
Comorbidity
Has 
problem (%)
Receives 
treatment (%)
Limits 
activity (%)
Back pain 342 (45) 142 (19) 226 (30)
Osteoarthritis 253 (34) 129 (17) 185 (25)
High blood 
pressure
235 (31) 226 (30) 22 (3)
Depression 148 (20) 117 (16) 63 (8)
Diabetes 77 (10) 63 (8) 11 (1)
Rheumatoid 
arthritis
70 (9) 40 (5) 51 (7)
Lung disease 29 (4) 23 (3) 18 (2)
Cancer 18 (2) 13 (2) 5 (<1)
Kidney disease 14 (2) 5 (<1) 3 (<1)
Liver disease 4 (<1) 1 (<1)   0
Ulcer or stomach 
disease
37 (5) 32 (4) 7 (1)
Other condition 1 372 (49) 280 (37) 150 (20)
Other condition 2 140 (19) 95 (13) 60 (8)
Other condition 3 48 (6) 30 (4) 20 (3)
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(LBP), osteoarthritis (OA) and high blood pressure, with 
LBP and OA also reported as the most activity limiting. 
Mean visual analogue scale score on the EQ-5D-3L was 
73.5 (SD=18.2), and the mean health utility index was 
0.66. Over 85% of respondents indicated having at least 
some pain and 31% of the cohort indicated having both 
pain and feeling anxious or depressed.
Using a multivariable regression model including age, 
sex, ethnicity, duration of CTS, smoking status, alcohol 
consumption, employment status, BMI and comorbidity 
score as potential confounding variables, a highly statis-
tically significant association was found between self-re-
ported symptom severity (using CTS-6 score) and anxiety, 
depression and HRQoL (p<0.0001 in each case). Table 4A 
gives the parameter estimates for psychological outcome 
and quality of life by self-reported and objectively graded 
severity. For each 1 point increase in score on the CTS-6 
there was an estimated 1.11 points increase in anxiety 
score, 1.43 points increase in depression score and a 10% 
mean decrease in health utility. Patients with the highest 
symptom severity (4–5 points on CTS-6) had mean 
anxiety scores of 9.62 (SD=5.48) indicating at least mild 
anxiety. There was a marked lower health utility for those 
with the highest symptom severity (scores 4–5 on CTS-6) 
with a mean health utility index of 0.43 compared with 
0.77 in the mildest group (scores 1–2 on CTS-6). When 
including the same independent variables in the model, 
objective severity grading based on NCS was significantly 
associated with anxiety (p=0.027), but not with depres-
sion or HRQoL. The association between NCS grade and 
anxiety, however, was negative with higher anxiety scores 
observed in severity grades 1 and 2 and the lowest mean 
anxiety scores observed in the worst severity group (mean 
3.42). For every one grade increase in neurophysiologi-
cally assessed severity there was an estimated 0.26 point 
decrease in the HADS anxiety score. Using the same multi-
variable regression model, a highly significant indepen-
dent association was also found between symptom severity 
and hand function subscales. For every 1 point increase 
in symptom severity, there was a marked decrease in hand 
function ranging from 13.4 to 17.8 points on the MHQ 
(see table 4B for parameter estimates by subscales). Elec-
trodiagnostic severity was also significantly associated with 
overall hand function and unilateral and bilateral activ-
ities of daily living but not with the work subscale. The 
magnitude of decline in hand function was less marked 
when using NCS grade in the model.
The mean cost of NHS service use per patient in 
the 3 months prior to baseline assessment was £447 
(SD=£274), with a societal cost (NHS plus patient out of 
pocket and lost productivity) of £636 (SD=£694). NHS 
costs comprised predominantly hospital visits including 
NCS (£362), general practitioner (GP) consultations 
(£58), prescription medications (£14) and other contacts 
and treatments (£13), which accounted for 70% of soci-
etal costs. Lost productivity (£101) accounted for 15% 
and out-of-pocket costs (£56 for lost wages due to GP/
hospital visits, £7 for travel to the hospital, £4 for hand 
splints, and £18 for other contacts and treatments for the 
remaining 15%). Although those individuals over the age 
of 40 generally have higher NHS and lower societal costs 
compared with 18–40 year-olds (reference category), 
age is not a significant predictor of costs under either 
perspective. For example, NHS costs are 15% higher 
on average for those individuals in the 81+ age group, 
when compared with 18–40 year-olds and accounting for 
NCS grade, but this, however, is not a significant determi-
nant of costs (p=0.327). NHS and societal costs, however, 
significantly increase with self-reported severity of CTS 
(p<0.01 and p<0.0001), but not NCS grade (p=0.269 and 
p=0.590). For every point increase in the self-reported 
severity, NHS and societal costs increase by 8% and 18%, 
respectively (see table 5).
dIsCussIOn
Principal findings
We found that at the point of referral for NCS and 
prior to any treatment, greater symptom severity 
was associated with greater psychological distress, 
poorer hand function and lower quality of life but 
not with worse electrodiagnostic abnormalities. Even 
after adjusting for known and potential confounders 
such as comorbidities, age, gender and BMI, we 
observed that every 1 point increase in symptom 
severity score was associated with an estimated 1.11 
points increase in mean anxiety score, a 1.43 points 
increase in depression score and a 0.10 decrease in 
health utility. Adjusting for the same independent 
variables, objectively graded severity from NCS, 
however, showed a significant negative association 
with anxiety and no significant association with 
depression or health utility. When modelling the 
outcome on self-reported hand function (MHQ), 
both symptom severity and NCS showed a significant 
association with overall hand function and activities 
of daily living, though the decrease in hand func-
tion was much more marked when using symptom 
severity (CTS-6). More than 40% of the variation 
in hand function was explained by the model when 
using CTS-6 score and less than 20% when using 
NCS grade in the model.
Average NHS and societal costs per patient were £447 
and £636, respectively. There was no significant associa-
tion between costs, age and objectively graded severity. 
We found, however, for every point increase in subjective 
severity, an 8% and 18% relative increase in NHS and soci-
etal costs, respectively.
Several other studies have explored the association 
of pain severity with a range of psychological variables 
including anxiety, depression, pain catastrophising 
and coping.9 10 21 These studies all conclude that illness 
behaviour is a stronger predictor of pain severity than 
objective measures of disease severity (NCS). In our study, 
we did not measure pain intensity, although the CTS-6 
does contain three items relating to pain (daytime pain, 
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nocturnal night and waking from pain). It should also be 
noted that pain is not always the predominant symptom.8
To the best of our knowledge, this is the first study to 
explore the association of self-reported and objectively 
graded symptom severity with psychological distress and 
quality of life using a multivariable model while adjusting 
for the effect of other confounders. It is also the first study 
to measure prospectively the NHS resource use and soci-
etal costs of patients with CTS. We included a wide range 
of variables which could account for increased psycho-
logical distress and decreased quality of life including 
comorbidities weighted by how activity limiting they 
are, smoking status, alcohol consumption, age, gender, 
ethnicity, employment status and duration of CTS.
A surprising finding is that objective severity assessed 
by NCS showed only a weak but negative association with 
anxiety, and there were no significant associations between 
NCS and HRQoL or NCS and depression. There has been 
much debate over the value of NCS in the diagnosis of 
CTS,1 22–24 and in the UK not all patients have NCS.7 Several 
studies have examined the association of self-reported symp-
toms and function with objective severity from electrodiag-
nostic findings. Most have used simple correlations with the 
exception of Chan et al.25 The latter used a multivariable 
model controlling for several demographic variables, as well 
as psychological measures including depression, somati-
sation and pain-related catastrophising, in a sample of 215 
patients with CTS. They conclude that subjective symptoms 
Table 5 Relationship between CTS severity, age and cost
n NHS cost (SD) Exp(b) (95% CI)* Societal cost (SD) Exp (b) (95% CI)*
CTS-6
  1.00 7 £512.83 (£405.61) £726.02 (£776.80)
  1.01–2.00 134 £434.04 (£212.53) £559.37 (£430.53)
  2.01–3.00 308 £422.57 (£220.30) £554.73 (£492.25)
  3.01–4.00 241 £466.50 (£348.74) £686.11 (£814.25)
  4.01–5.00 63 £511.52 (£273.65) 1.08 (1.03 to 1.12) p<0.01 £984.19 (£1197.94) 1.18 (1.10 to 1.27)
p<0.0001
NCS grade
  1 150 £483.36 (£456.12) £629.69 (£608.90)
  2 79 £459.44 (£243.93) £592.70 (£381.55)
  3 202 £438.50 (£213.31) £657.58 (£755.06)
  4 137 £414.14 (£153.80) £578.23 (£597.95)
  5 159 £439.38 (£203.02) £676.24 (£892.99)
  6 24 £467.71 (£237.77) 0.98 (0.96 to 1.01) p=0.269 £583.77 (£294.98) 1.01 (0.96 to 1.07)
p=0.590
Age and CTS-6
  Ages 18–40 43 £433.41 (£178.60) £758.67 (£1099.72)
  Ages 41–60 344 £444.53 (£226.94) 1.04 (0.88 to 1.22) p=0.679 £613.03 (£533.45) 0.83 (0.63 to 1.10)
p=0.196
  Ages 61–80 322 £451.96 (£336.62) 1.13 (0.94 to 1.36) p=0.190 £631.64 (£731.18) 0.90 (0.66 to 1.22)
p=0.486
  Ages 81+ 44 £442.46 (£146.20) 1.16 (0.91 to 1.47) p=0.224 £712.66 (£973.69) 1.09 (0.73 to 1.62)
p=0.690
Age and NCS grade
  Ages 18–40 43 £433.41 (£178.60) £758.67 (£1099.72)
  Ages 41–60 343 £443.81 (£226.88) 1.02 (0.87 to 1.21) p=0.774 £608.42 (£527.83) 0.81 (0.60 to 1.09)
p=0.163
  Ages 61–80 321 £451.29 (£336.93) 1.11 (0.93 to 1.34) p=0.246 £629.87 (£730.63) 0.85 (0.61 to 1.18)
p=0.336
  Ages 81+ 44 £442.46 (£146.20) 1.15 (0.90 to 1.47) p=0.252 £712.65 (£973.69) 0.99 (0.64 to 1.53)
p=0.976
*Exponentiated parameter estimate (SE) from a generalised linear model with log-link and gamma distributed errors including gender, age, 
ethnicity, employment status, smoking status, units of alcohol per week, body mass index, bilateral CTS, comorbidities and comorbidity 
score.
CTS, carpal tunnel syndrome; NCS, nerve conduction studies; NHS, National Health Service.
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and objective severity are independent of each other. One 
possible explanation is that NCS can only measure the velocity 
and amplitude of large myelinated fibres that is sensory and 
motor axons. Yet CTS also affects the small unmyelinated 
fibres,26 and it is these which account for the neuropathic 
pain component manifesting as pain during daytime and 
night-time. Only three out of the six questions in the CTS-6 
address sensory symptoms (daytime numbness or tingling, 
night-time numbness or tingling, and waking from numb-
ness and tingling), with the other three questions relating to 
pain at night, in the day and waking due to pain. Patients with 
more severe electrodiagnostic CTS (grades 5 and 6) have 
numbness and even muscle wasting but often do not have 
any ‘positive’ symptoms such as tingling or pain resulting in 
a lower overall self-reported symptom score. It has also been 
suggested that those with more severe compression often 
have less subjective symptoms, especially in older patients in 
whom there is a natural age-related decline in sensory func-
tion and reduced pain sensitivity27 but greater functional 
disability.28 This may also explain the significant association 
observed between NCS grade and hand function (MHQ) as 
severe numbness and thenar wasting found in grades 5 and 6 
are likely to have a greater impact on hand function.
Another reason for the lack of association with nerve 
conduction results is that CTS causes small fibre loss not 
detected by NCS and, surprisingly, in some people with more 
severe nerve entrapment subjective symptoms and function 
improve suggesting an adaptive mechanism.26
The slight association of anxiety with very mild or 
mild electrophysiological abnormalities of the median 
nerve CTS could represent disproportionate concern 
about mild symptoms from mild disease (the essence of 
anxiety), misdiagnosis of CTS with incidental mild elec-
trophysiological abnormalities or a reaction to dismissive 
clinicians.
Our analysis, being cross sectional, cannot address the 
question of whether anxiety and depression are the cause 
or the effect of self-reported symptom severity. There may 
well be a bidirectional relationship between symptom 
severity and psychological distress, where each contributes 
to the development and is a consequence of the other. 
Neither can we conclude from these data that if symptom 
severity improves after treatment then psychological distress 
or quality of life would also improve. A possible explana-
tion for the significant independent association between 
self-reported symptoms, psychological status and HRQoL 
is that people either consistently underplay or exaggerate 
their symptoms, irrespective of whether these are physical, 
psychological or global HRQoL. This may also explain the 
increased costs, both from an NHS and personal perspec-
tive, driven by increased treatment-seeking behaviour in 
those who perceive their symptoms as worse.
HRQoL was markedly lower in those with very severe 
self-reported symptoms (scores 4–5 on CTS-6). Their mean 
health utility of 0.43 is much lower than that reported in other 
studies of patients with CTS prior to surgery ranging from 
0.74 to 0.81 using the EQ-5D and 0.69 using the SF-36 (Short 
Form-36) or SF-6D (Short Form-6 dimension).29–31 In fact, 
the mean utility index for this group is closer to that reported 
by EQ-5D in people with serious diseases like severe heart 
failure,32 moderate to severe psychotic illness33 and digestive 
system cancers.34
strengths and limitations
The strengths of the present study include its prospec-
tive design, multicentre recruitment and a large sample 
size (>700) in whom a wide range of prespecified socio-
demographic and clinical variables were collected at base-
line. Using a multivariable model mitigates the potentially 
confounding factors such as age, comorbidities, and so on, 
by adjusting for these and thus testing the independence of 
any associations between self-reported or neurophysiological 
severity and psychological distress, hand function or quality 
of life.
There are also limitations, namely that the data collection 
was reliant on patient self-report which is open to recall bias, 
and data quality could not be independently verified. For 
example, duration of symptoms may be difficult to attribute 
separately to each hand in the case of bilateral symptoms or 
to remember accurately over a longer period. Patients were 
recruited through secondary care having been referred by a 
primary care physician. It is therefore possible that our study 
sample is biased towards those actively seeking treatment for 
their CTS. Long-term follow-up over 2 years is under way 
and will allow us to explore predictors of treatment-related 
outcomes and cost. We were also not able to explain why 
costs were higher for the lowest and highest CTS-6 grades, 
although it should be borne in mind that these costs relate 
only to the 3 months prior to entry in the study. The 2-year 
follow-up data will provide a more robust analysis. Finally, 
our sample is biased towards an older age group and may 
not be representative of the typical clinical population with 
CTS.
COnClusIOns
This study shows that even when accounting for potential 
confounders such as, for example, comorbidities or age, a 
strong and highly significant association remains between 
symptom severity and psychological status and HRQoL. 
This means that those with more severe symptoms are also 
more likely to present with worst mental health, poorer hand 
function and lower quality of life, thus placing a significant 
burden on the individual, health services and society. There-
fore, access to timely and effective diagnostics and effective 
treatment before symptoms become severe or very severe 
is paramount. NCS remains a useful tool to assess disease 
severity, which in turn should be used to determine whether 
surgery is indicated or not; however, NCS should not be used 
as a measure of the impact of CTS on the person. Patients 
presenting with only mild disease severity on NCS but who 
exhibit anxiety or depression may need to be offered addi-
tional psychological support.
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